We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Bacterial Target Identified for Early Detection of Noma

By LabMedica International staff writers
Posted on 01 Apr 2026

Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. More...

Without treatment, it is fatal in up to 90% of cases, and survivors face severe disfigurement and lifelong complications. Most cases are identified too late, when significant tissue damage has already occurred. Researchers now report a microbial discovery that could enable earlier diagnosis and more effective treatment.

Liverpool School of Tropical Medicine (LSTM) researchers, working with the University of Liverpool, Médecins Sans Frontières, and the Noma Children’s Hospital in Sokoto, Nigeria, applied shotgun metagenomic sequencing and machine-learning algorithms to saliva samples from children with acute noma. The analyses uncovered a previously undescribed Treponema species that was strongly associated with the disease. Treponema bacteria were also detected in early disease stages, suggesting they may play a key role in triggering progression from gingivitis to noma.

Further analysis indicated the identified bacteria did not harbor known antibiotic resistance genes, implying potential susceptibility to existing antibiotic treatments when detected early. The investigators also observed a disrupted oral microbiome in affected children, with Treponema taxa appearing more common and bacteria typical of a healthy mouth diminished. Together, these findings point to a consistent microbial signature for noma that could support earlier detection.

The research is published in PLOS Neglected Tropical Diseases. Noma was formally classified as a neglected tropical disease by the World Health Organization in 2023. According to the team, the discovery opens a path toward diagnostic tools that can identify the disease at its earliest stages, when treatment is most effective. The identification of a consistent microbial pattern marks a step forward in understanding this long-neglected condition and brings renewed hope for prevention, diagnosis, and treatment.

“We found that the composition of bacteria in children with noma is completely disrupted. Some bacteria, such as those in the Treponema genus, appear to be more common, while others that are usually part of a healthy mouth almost disappear. That imbalance gives us important clues about how the disease starts and progresses,” said Richard Goodman, joint lead author at Liverpool School of Tropical Medicine.

“Noma is a disease that simply should not exist, but up until now we have lacked a detailed understanding of the microbes involved. By using metagenomic sequencing, we can now see the full bacterial community in unprecedented detail. This has allowed us to identify a species of Treponema bacteria strongly linked to the disease,” said Adam Roberts, Professor at the Liverpool School of Tropical Medicine’s Center for Neglected Tropical Diseases.

Related Links
Liverpool School of Tropical Medicine (LSTM)


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.